2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Gene Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult, Animal Model
PAPER

3157 A novel chronic mouse model of aplastic anemia reveals mechanisms of disease persistence and therapeutic targets

Yuta Yamada, MD, PhD, Masayuki Yamashita, MD, PhD2
1 St.jude Children's Research Hospital, Memphis, Tennessee, United States
2 St.jude Children's Research Hospital, Memphis, Tennessee, United States

Idiopathic aplastic anemia (IAA) is an immune-mediated bone marrow (BM) failure syndrome in which autoreactive CD8+ cytotoxic T cells destroy hematopoietic stem cells (HSCs). Although most patients initially respond to immunosuppressive therapy, approximately 40% eventually relapse. Persistent antigen-specific memory T cells are thought to contribute to disease persistence and relapse. However, the mechanisms by which these cells sustain chronic disease remain poorly understood. Although several mouse models have provided insights into IAA pathogenesis, their rapid progression to lethal BM failure and the paucity of patient BM samples have limited studies of disease persistence and therapeutic interventions in established disease. We therefore developed a chronic mouse model of IAA.

To establish an antigen-specific model of IAA, we transplanted whole BM from Act-mOVA mice, which ubiquitously express the model antigen ovalbumin (OVA), into irradiated recipient mice to restrict OVA expression to the hematopoietic compartment, followed by adoptive transfer of OVA-specific CD8+ (OT-I) and CD4+ (OT-II) T cells. Co-transfer, but not transfer of either cell type alone, induced pancytopenia at 2 weeks, including marked depletion of BM reticulocytes, followed by leukopenia lasting more than 3 months without mortality (P = 0.011).

In the co-transfer group, OT-derived cells represented approximately 50% of peripheral blood (PB) CD4+ T cells and 25% of CD8+ T cells at 2 weeks, whereas they were nearly absent in the other groups. Memory subset analysis showed that most OT-derived cells exhibited a CD44+ CD62L− effector memory T-cell (TEM) phenotype, with few CD44− CD62L+ naïve cells, and were enriched in the BM and spleen relative to PB. The TEM-rich OT-derived population emerged by day 6 and persisted for at least 3 months despite a gradual decline in frequency. Notably, mice with leukopenia persisting beyond 4 months maintained a high proportion of OT-derived cells without decline, implicating persistent antigen-specific TEM cells in chronic leukopenia.

To determine whether persistent leukopenia reflected bona fide BM failure at the HSC level, we examined inflammatory and hematopoietic changes within the BM. During the pancytopenic phase, only the co-transfer group exhibited elevated TNF-α (P = 0.0048) and IFN-γ (P = 0.0286) levels in BM supernatants, consistent with findings in patients with IAA. Consistent with this inflammatory milieu, Sca-1 expression on c-Kit+ cells was increased but returned to baseline by 3 weeks. Moreover, hematopoietic analysis revealed selective depletion of EPCR+ HSCs (Lin− c-Kit+ Sca-1+ CD48− CD150+ EPCR+) at 2-3 weeks (P = 0.0215), a defect that persisted through day 140, particularly in mice with ongoing leukopenia. These findings demonstrate that the co-transfer model recapitulates key BM pathologic features of IAA.

The requirement for OT-II cells to sustain OT-I TEM cells and the HSC impairment suggested a critical role for CD4+ T-cell help in persistent cytopenia. We therefore investigated CD4+ T-cell differentiation in the BM. During the pancytopenic phase, OT-derived CD4+ T cells in the co-transfer group rarely differentiated into regulatory T cells (Tregs) and instead predominantly expressed the Th17-associated transcription factor RORγt, whereas RORγt+ cells were nearly absent in the other groups. This skewed phenotype was enriched in the BM relative to the spleen and extended beyond OT-derived cells, as endogenous CD4+ T cells likewise showed increased RORγt expression. Consequently, the frequency of BM RORγt+ CD4+ T cells increased (P = 0.0002), whereas Treg frequencies decreased (P = 0.0441), mirroring immune abnormalities reported in patients with IAA. Notably, these alterations persisted through day 140, even in co-transfer mice that lacked detectable OT-derived cells and no longer exhibited leukopenia. These findings suggest that a RORγt-skewed immune environment may support the maintenance of pathogenic antigen-specific CD8+ TEM cells but is insufficient on its own to drive disease persistence.

Taken together, our findings demonstrate that antigen-specific CD4+ and CD8+ T cells cooperate to drive persistent cytopenia and HSC impairment in chronic IAA. Our model defines the dynamics of pathogenic memory T cells and chronic immune dysregulation, providing new insight into the mechanisms underlying disease persistence and relapse in IAA.

Yuta Yamada, MD, PhD: No relevant conflicts of interest to declare.